Pluristyx, a provider of tools, technologies, and services for cell therapies, has released its cryopreservation medium solution, PluriFreeze. Currently available in a Research Use Only (RUO) formulation, with a Good Manufacturing Practice (GMP) version to be released in future, PluriFreeze adds to the company’s Pluristyx’s panCELLa Platform for iPSC therapeutic development, with broad applicability for other sensitive cell types.
Charles River Collaborates with Pluristyx
Pluristyx and panCELLa Expand Intellectual Property Portfolio for Pluripotent Stem Cell Cloaking Technology
SEATTLE--(BUSINESS WIRE)--Today, Pluristyx, panCELLa, and Implant Therapeutics management are excited to announce their corporate merger, pending shareholder approval. The merged company will combine complementary portfolios to offer end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services. The integrated technological and service offerings will greatly accelerate the development and delivery of revolutionary cell therapies to patients.
Pluristyx, an advanced therapy tools and services biotechnology company, and Accelerated Biosciences, a regenerative medicine innovator in the use of proprietary human trophoblast stem cells (hTSCs), signed an agreement for Pluristyx to manufacture clinical grade hTSC banks under Good Manufacturing Practices (GMP). Accelerated Biosciences will use and make these stem cell banks available to commercial partners for further manufacturing of advanced biologic and cellular therapies. hTSCs have unique legal, ethical, and intellectual property advantages, including a high expansion capacity and a unique genetic identity not associated with any person or embryo, making them the ideal starting material for manufacturing the next generation of advanced therapies.
SEATTLE--(BUSINESS WIRE)--Pluristyx, Inc., a leading chemistry, manufacturing, and controls (CMC), consulting, process development, and tools provider for cell and gene therapy companies, today announced it will be supporting a collaboration between Kiadis Pharma (Kiadis), and the Advanced Regenerative Manufacturing Institute’s (ARMI) BioFabUSA program working on Kiadis’ COVID-19 research and development program, Kiadis’ Natural Killer cells, (K-NK-ID101) as a universal countermeasure to fight COVID-19 and future pandemics.